Landos Biopharma Stock (NASDAQ:LABP), Analyst Ratings, Price Targets, Predictions

The latest price target for Landos Biopharma (NASDAQ: LABP) was reported by HC Wainwright & Co. on April 1, 2024. The analyst firm set a price target for $20.42 expecting LABP to fall to within 12 months (a possible -8.51% downside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Landos Biopharma (NASDAQ: LABP) was provided by HC Wainwright & Co., and Landos Biopharma downgraded their neutral rating.

There is no last upgrade for Landos Biopharma.

The last downgrade for Landos Biopharma Inc happened on April 1, 2024 when HC Wainwright & Co. changed their price target from $50 to $20.42 for Landos Biopharma Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Landos Biopharma, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Landos Biopharma was filed on April 1, 2024 so you should expect the next rating to be made available sometime around April 1, 2025.

While ratings are subjective and will change, the latest Landos Biopharma (LABP) rating was a downgraded with a price target of $50.00 to $20.42. The current price Landos Biopharma (LABP) is trading at is $22.32, which is out of the analyst’s predicted range.